Pacira Pharmaceuticals, Inc. (PCRX)

[surf1944]

First, Pacira Pharmaceuticals(PCRX_) is expecting an FDA approval decision on Oct. 28 for Exparel in post-surgical pain management. Exparel is a proprietary, long-acting formulation of the painkiller bupivacaine. FDA extended the Exparel review by three months because Pacira submitted additional information.

I met with Pacira executives a couple of weeks ago and walked out confident in Exparel's approval. The three-month delay sounded much more procedural than anything worrisome.

http://www.thestreet.com/_yahoo/story/11185692/1/biotech-stock-mailbag-adventrx-pharma.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA